Literature DB >> 33230065

ANALYSIS OF FLUID VOLUME AND ITS IMPACT ON VISUAL ACUITY IN THE FLUID STUDY AS QUANTIFIED WITH DEEP LEARNING.

Gregor S Reiter1, Christoph Grechenig1, Wolf-Dieter Vogl1, Robyn H Guymer2, Jennifer J Arnold3, Hrvoje Bogunovic1, Ursula Schmidt-Erfurth1.   

Abstract

PURPOSE: To investigate quantitative differences in fluid volumes between subretinal fluid (SRF)-tolerant and SRF-intolerant treat-and-extend regimens for neovascular age-related macular degeneration and analyze the association with best-corrected visual acuity.
METHODS: Macular fluid (SRF and intraretinal fluid) was quantified on optical coherence tomography volumetric scans using a trained and validated deep learning algorithm. Fluid volumes and complete resolution was automatically assessed throughout the study. The impact of fluid location and volumes on best-corrected visual acuity was computed using mixed-effects regression models.
RESULTS: Baseline fluid quantifications for 348 eyes from 348 patients were balanced (all P > 0.05). No quantitative differences in SRF/intraretinal fluid between the treatment arms was found at any study-specific time point (all P > 0.05). Compared with qualitative assessment, the proportion of eyes without SRF/intraretinal fluid did not differ between the groups at any time point (all P > 0.05). Intraretinal fluid in the central 1 mm and SRF in the 1-mm to 6-mm macular area were negatively associated with best-corrected visual acuity (-2.8 letters/100 nL intraretinal fluid, P = 0.007 and -0.20 letters/100 nL SRF, P = 0.005, respectively).
CONCLUSION: Automated fluid quantification using artificial intelligence allows objective and precise assessment of macular fluid volume and location. Precise determination of fluid parameters will help improve therapeutic efficacy of treatment in neovascular age-related macular degeneration.

Entities:  

Mesh:

Year:  2021        PMID: 33230065     DOI: 10.1097/IAE.0000000000003023

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.

Authors:  Ursula Schmidt-Erfurth; Zufar Mulyukov; Bianca S Gerendas; Gregor S Reiter; Daniel Lorand; Georges Weissgerber; Hrvoje Bogunović
Journal:  Eye (Lond)       Date:  2022-05-06       Impact factor: 3.775

2.  Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Authors:  David R Lally; Anat Loewenstein; Jennifer J Arnold; Yit C Yang; Kinfemichael Gedif; Catherine Best; Hersh Patel; Ramin Tadayoni; Jeffrey S Heier
Journal:  Eye (Lond)       Date:  2022-05-21       Impact factor: 3.775

3.  [Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD].

Authors:  H Faatz; N Feltgen; M Gutfleisch; B Heimes-Bussmann; T U Krohne; S Liakopoulos; R Liegl; A Lommatzsch; P Mussinghoff; M Rehak; S Schmitz-Valckenberg; G Spital; B Stanzel; F Ziemssen; B Hägele; C Junkes; M Porstner; J Vögeler; B Gmeiner; D Pauleikhoff
Journal:  Ophthalmologie       Date:  2022-09-20

4.  Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.

Authors:  Leonard M Coulibaly; Stefan Sacu; Philipp Fuchs; Hrvoje Bogunovic; Georg Faustmann; Christian Unterrainer; Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2022-07-05       Impact factor: 4.456

Review 5.  Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan.

Authors:  Cheng-Kuo Cheng; Shih-Jen Chen; Jiann-Torng Chen; Lee-Jen Chen; San-Ni Chen; Wen-Lu Chen; Sheng-Min Hsu; Chien-Hsiung Lai; Shwu-Jiuan Sheu; Pei-Chang Wu; Wei-Chi Wu; Wen-Chuan Wu; Chung-May Yang; Ling Yeung; Ta-Ching Chen; Chang-Hao Yang
Journal:  BMC Ophthalmol       Date:  2022-01-15       Impact factor: 2.209

6.  Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment.

Authors:  Han Joo Cho; Mi Yeon Song; Wontae Yoon; Jihyun Yoon; Seung Kwan Na; Jihyun Lee; Jaemin Kim; Jong Woo Kim
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

7.  Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study).

Authors:  Somanus Thoongsuwan; Prut Hanutsaha; Yodpong Chantarasorn; Paisan Ruamviboonsuk; Sritatath Vongkulsiri; Pavinee Kungwanpongpun
Journal:  Ophthalmol Ther       Date:  2022-02-11

Review 8.  Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy.

Authors:  Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Ther Adv Ophthalmol       Date:  2022-03-23

9.  A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea.

Authors:  Jae Hui Kim; Min Sagong; Se Joon Woo; Yu Cheol Kim; Heeyoon Cho; Young Hoon Lee; Iksoo Byon; Young Joon Jo; Hee Seung Chin; Youkyung Lee; Jae Eun Chae; Se Woong Kang
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

10.  Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation.

Authors:  Reinhard Angermann; Alexander Franchi; Victoria Stöckl; Julia Rettenwander; Tanja Rettenwander; David Goldin; Martin Stattin; Martina T Kralinger; Claus Zehetner
Journal:  Ophthalmol Ther       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.